Immunology Drugs Market Overview | Europe | 2018-2024 | MedView

  • Year: 2018
  • Scope: 2014-2024
  • Region: Europe
  • Pages: 938
  • Published Date: 10/1/2017
  • Type: MedView

Product Description

The report is an extensive market analysis study on the current biologics such as ORENCIA®, HUMIRA®, CIMZIA®, Enbrel®, SIMPONI®, REMICADE®, RITUXAN®, Actemra®, STELARA®, ENTYVIO®, XELJANZ® and TYSABRI ®. Some of these biologics are approved and used in more than one conditions. Therefore, the market has been segmented by diseases such as rheumatoid arthritis, Crohn`s Disease, Ankylosing Spondylitis, Psoriasis and Ulcerative Colitis.
 

FREE Sample Report

To request the Table of Contents of this report, please contact info@idataresearch.net Our Product Advisors will answer any questions you may have regarding the contents of this report.
To request the Table of Contents of this report, please contact info@idataresearch.net Our Product Advisors will answer any questions you may have regarding the contents of this report.
To request the Table of Contents of this report, please contact info@idataresearch.net Our Product Advisors will answer any questions you may have regarding the contents of this report.
To request the Table of Contents of this report, please contact info@idataresearch.net Our Product Advisors will answer any questions you may have regarding the contents of this report.

iData’s 9-Step Research Methodology

Our reports follow an in-depth 9-step methodology which focuses on the following research systems:

  • Original primary research that consists of the most up-to-date market data
  • Strong foundation of quantitative and qualitative research
  • Focused on the needs and strategic challenges of the industry participants

Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.

Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.

Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.

Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.

Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.

Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.

Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.

Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.

Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.

Click Here to Read More About Our Methodology

Explore Options

Report Summary

FREE

Select License Type

The Europe immunology market includes biologic drugs that are used in the treatment of various immunology diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn`s disease (CD), ulcerative colitis (UC) and psoriasis (PsO). As there is a need for cost effective drugs in treating these diseases, there is an increased number of drugs in development for these diseases. Current treatment mainly constitutes NSAIDs and biologics.

  • 2018
  • 2014-2024
  • Europe
  • 10/1/2017
  • 938
  • MedView
SKU: iDATA_EUIM18_MV Category:
0
    0
    Your Cart
    Your cart is emptyReturn to Report Library